Eledon Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eledon Pharmaceuticals generated cash of -$39,527,000, which is less than the previous year. Cash used in financing activities reached the amount of $33,017,000 last year. Net change in cash is therefore -$51,797,000.
Cash Flow
| 2014 | -21.12M | -175K | 94.79M |
|---|---|---|---|
| 2015 | -41.23M | -40.51M | 513K |
| 2016 | -36.52M | 35.68M | 37K |
| 2017 | -14.94M | 23.25M | 7.86M |
| 2018 | -11.89M | 0 | 7.56M |
| 2019 | -13.85M | 0 | 9.67M |
| 2020 | -15.21M | 11.03M | 109.58M |
| 2021 | -28.91M | 0 | -449K |
| 2022 | -28.42M | 0 | 0 |
| 2023 | -39.52M | -45.28M | 33.01M |
ELDN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 56.40M | 84.83M | 114.19M | 8.79M | 12.97M | 17.30M | 1.11M | 24.02M | 105.25M | 31.75M |
Operating activities | ||||||||||
Net income | -116.53M | -87.96M | -34.50M | -22.81M | -16.01M | -14.06M | -13.11M | -37.95M | -45.08M | -23.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 374K | 373K | 195K | 183K | 182K | 11K | 22K | 171K | 109K | 21K |
Stock-based compensation expense | 6.54M | 8.15M | 7.90M | 3.17M | 1.30M | 0 | 579K | 3.00M | 2.90M | 2.10M |
| Deferred income tax benefit | 6.54M | 8.15M | 7.90M | 3.17M | 1.30M | 0 | 579K | 3.00M | 2.90M | 2.10M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 149 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.6M | 2.08M | 2.14M | -39K | -1.39M | 1.09M | -1.95M | -778K | 443K | 760K |
Cash generated by operating activities | -39.52M | -28.42M | -28.91M | -15.21M | -13.85M | -11.89M | -14.94M | -36.52M | -41.23M | -21.12M |
Investing activities | ||||||||||
Purchases Of Investments | -78.28M | 0 | 0 | 0 | 0 | 0 | 0 | -500K | -39.87M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17K | -565K | -25K |
Acquisitions Net | 0 | 0 | 0 | 11.03M | 0 | 0 | 23.25M | -2K | 0 | 0 |
Cash generated by investing activities | -45.28M | 0 | 0 | 11.03M | 0 | 0 | 23.25M | 35.68M | -40.51M | -175K |
Financing activities | ||||||||||
Common Stock Issued | 33.01M | 0 | -449K | 9M | 9.67M | 7.49M | 4.75M | 0 | 464K | 97.92M |
Payments for dividends | 0 | 0 | 0 | -25K | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -25 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -25 | 0 | 0 | 0 | -2.93M | 0 | 0 |
Cash used in financing activities | 33.01M | 0 | -449K | 109.58M | 9.67M | 7.56M | 7.86M | 37K | 513K | 94.79M |
Net Change In Cash | -51.79M | -28.42M | -29.36M | 105.40M | -4.18M | -4.33M | 16.18M | -800K | -81.23M | 73.50M |
Cash at end of period | 4.61M | 56.40M | 84.83M | 114.19M | 8.79M | 12.97M | 17.30M | 23.22M | 24.02M | 105.25M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |